The FDA has officially approved the use of CAR-Ts that target the CD19 antigen for the treatment of refractory acute lymphoblastic leukemia/lymphoma, mantle cell lymphoma, and large B cell lymphomas (51–53). Here, CD19 is linked to acute lymphoblastic leukemia.